STOCK TITAN

Burning Rock Publishes 2023 Annual Report on Form 20-F

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Burning Rock Biotech (BNR), a precision oncology company, published its 2023 Annual Report on Form 20-F, filing it with the SEC. The report is accessible on the SEC and company websites, highlighting financial and operational performance.

Burning Rock Biotech (BNR), un'azienda specializzata in oncologia di precisione, ha pubblicato il suo Rapporto Annuale 2023 sul Modulo 20-F, presentandolo alla SEC. Il rapporto è disponibile sui siti web della SEC e della compagnia, evidenziando le prestazioni finanziarie e operative.
Burning Rock Biotech (BNR), una compañía de oncología de precisión, publicó su Informe Anual 2023 en el Formulario 20-F, presentándolo ante la SEC. El informe está accesible en las páginas web de la SEC y de la empresa, destacando el desempeño financiero y operativo.
정밀 종양학 회사인 버닝 록 바이오텍(Burning Rock Biotech, BNR)은 2023년 연차 보고서를 Form 20-F로 작성하여 SEC에 제출했습니다. 이 보고서는 SEC와 회사 웹사이트에서 접근 가능하며, 재무 및 운영 성과를 강조합니다.
Burning Rock Biotech (BNR), une entreprise d'oncologie de précision, a publié son Rapport Annuel 2023 sur le formulaire 20-F, le déposant auprès de la SEC. Le rapport est accessible sur les sites Web de la SEC et de l'entreprise, mettant en lumière la performance financière et opérationnelle.
Burning Rock Biotech (BNR), ein Unternehmen für Präzisionsonkologie, hat seinen Jahresbericht 2023 auf dem Formular 20-F veröffentlicht und bei der SEC eingereicht. Der Bericht ist auf den Websites der SEC und des Unternehmens zugänglich und hebt die finanzielle und betriebliche Leistung hervor.
Positive
  • None.
Negative
  • None.

GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company’s website at http://ir.brbiotech.com. The Form 20-F has also been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR; LSE: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: http://ir.brbiotech.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com


FAQ

When was Burning Rock Biotech 's 2023 Annual Report on Form 20-F published?

Burning Rock published its 2023 Annual Report on Form 20-F on April 29, 2024.

Where can I access Burning Rock Biotech 's Form 20-F?

The Form 20-F can be viewed on the SEC website at www.sec.gov and the company's website at http://ir.brbiotech.com.

Which organization is responsible for the filing and inspection of Burning Rock Biotech 's Form 20-F?

The National Storage Mechanism is responsible for the filing and inspection of Burning Rock Biotech 's Form 20-F.

Burning Rock Biotech Limited

NASDAQ:BNR

BNR Rankings

BNR Latest News

BNR Stock Data

82.38M
56.48M
0.12%
61.06%
0.39%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
Guangzhou

About BNR

Headquartered in China and founded in 2014, Burning Rock, whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.